P202 AS A Potential Therapeutic Gene for Breast Cancer
Abstract
The main goal of this proposal is to study the anti-tumor activity of p202 and its application in a breast cancer model system. Three specific aims are 1) To determine the effects of p202 on the sensitivity of breast cancer cells to anticancer agents; 2) To test the anti-tumor activity of p202 in breast cancer cells using preclinical gene therapy strategies in an orthotopic breast cancer animal model; and 3) To evaluate the therapeutic efficacy of p202 gene therapy in combination with other anti-cancer agents in an orthotopic breast cancer animal model. We have developed a p202-based therapeutic agent to study its efficacy in animal models in the first year of grant supported period. Our results have shown that adenovirus-mediated p202 gene transfer and its expression can cause growth-suppression and sensitization to TNF-a, taxol, CDDP and sigma-irradiation induced apoptosis of breast cancer cells. In the last year, we have completed CMV-p202-liposome delivery system in vivo via intratumoral and i.v. injection, and immunohistostaining in p202-treated breast cancer cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2003
- Accession Number
- ADA416154
Entities
People
- Mien-Chie Hung
Organizations
- The University of Texas MD Anderson Cancer Center